Innovation Pharmaceuticals Inc (IPIX)

[PlentyParanoid]

No they did not. There is better, more informative, Galera GC4419 data set here.

Galera's CG4419 is one of those funny compounds that looks worse every time when additional data is provided. Don't take me wrong, GC4419 is still far better than anything currently available for everyday use, but the latest data does not live up to Galera's early press releases.

The rest follows SS's and the Carrot Chomper's way of informing people (ie. giving away nuttin')

As a game I recommend gazing intently - as if thinking (TIAB: 'the diagnosis stare') - above linked slides titled:
- GC4419 Phase 2b Enrollment & Assignment
- Primary Endpoint – Duration of SOM (Grade 3+4)
- Secondary Endpoint – Incidence of SOM (Grade 3+4), Thru 60 Gy
- Secondary Endpoint – Incidence of SOM (Grade 3+4), Thru all IRMT
and prettiest of the them all (mirror, mirror...)
- Individual Patient “Swimmers’ Plot” — 90 mg v PBO

The game score:
count how many WTF moments you had.
Homework if no WTF moments experienced:
1. Try to reconcile the above slides with each other.
2. Essay: What is FDA's preferred trial population for use in analysis and why?
Extra bonus:
See what you get when you convert the swim lane plots (as people outside clinical trial arts have called it for decades) to Kaplan-Meier graph for SOM incidence GC4419 90 mg vs placebo.